Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation

Transplantation Proceedings

Volumn 47, Issue 3, 2015, Pages 644-648

  Nakao, T ^a   Ushigome, H ^a   Kawai, K ^a   Nakamura, T ^a   Harada, S ^a   Koshino, K ^a   Suzuki, T ^a   Ito, T ^a   Nobori, S ^a   Yoshimura, N ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; BLOOD GROUP ANTIBODY; CD20 ANTIGEN; CYCLOSPORIN; MIZORIBINE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB; TACROLIMUS; BLOOD GROUP ABO SYSTEM; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY TITER; B LYMPHOCYTE; BACTERIAL INFECTION; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW SUPPRESSION; CAUSE OF DEATH; CONFERENCE PAPER; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RATE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LIVING DONOR KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PLASMAPHERESIS; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; VIRUS INFECTION; AGED; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUP TYPING; DOSE RESPONSE; DRUG ADMINISTRATION; EVALUATION STUDY; GRAFT REJECTION; IMMUNOLOGY; MORTALITY; TREATMENT OUTCOME;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUPING AND CROSSMATCHING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84928329710     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2014.12.033     Document Type: Conference Paper

References (9)

1. T. Sawada, S. Fuchinoue, and S. Teraoka Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis Transplantation 74 2002 1207
2. D. Tsai, H. Moore, and C. Hardy Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation Bone Marrow Transplant 24 1999 521
3. S. Kaihara, M. Okamoto, and K. Akioka Improved graft survival in ABO-incompatible living donor kidney transplantation Transplant Proc 37 2005 1804
4. S. Ashimine, Y. Watarai, and T. Yamamoto Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation Kidney Int 85 2014 425
5. S. Hatakeyama, T. Fujita, and R. Murakami Outcome comparison of ABO-incompatible kidney transplantation with low-dose rituximab and ABO-compatible kidney transplantation: a single-center experience Transplant Proc 46 2014 445
6. H. Egawa, S. Teramukai, and H. Haga Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study Am J Transplant 14 2014 102
7. C. Silvestre, L. Furian, and P. Marson Desensitization with plasmapheresis and anti-Cd20 for ABO incompatible kidney transplantation from living donor: experience of a single center in Italy Transplant Proc 46 2014 2209
8. B.H. Chung, Y.A. Hong, and I.O. Sun Determination of rituximab dose according to immunologic risk in ABO-incompatible kidney transplantation Ren Fail 34 8 2012 974 979
9. D. Won, W. Choe, and H.J. Kim Significance of isoagglutinin titer in ABO-incompatible kidney transplantation J Clin Apher 29 5 2014 243 250